Real-time Estimate
Cboe BZX
11:51:23 2024-05-24 am EDT
|
5-day change
|
1st Jan Change
|
11.34
USD
|
+0.53%
|
|
-5.30%
|
-24.55%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,109
|
3,808
|
1,149
|
1,072
|
801
|
-
|
-
|
Enterprise Value (EV)
1 |
1,771
|
3,468
|
712
|
589.2
|
272.6
|
445.2
|
445.8
|
P/E ratio
|
-12.4
x
|
-22.6
x
|
-4.5
x
|
-3.39
x
|
-4.12
x
|
-3.03
x
|
-4.03
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
25
x
|
266
x
|
11
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
8.52
x
|
148
x
|
6.15
x
|
EV / EBITDA
|
-14.9
x
|
-16.1
x
|
-3.15
x
|
-1.98
x
|
-1.17
x
|
-1.52
x
|
-1.49
x
|
EV / FCF
|
-13.9
x
|
-16.9
x
|
-3.3
x
|
-2.83
x
|
-1.17
x
|
-1.55
x
|
-1.65
x
|
FCF Yield
|
-7.21%
|
-5.92%
|
-30.3%
|
-35.4%
|
-85.3%
|
-64.4%
|
-60.7%
|
Price to Book
|
6.91
x
|
10.5
x
|
2.75
x
|
2.45
x
|
1.78
x
|
2.91
x
|
3.22
x
|
Nbr of stocks (in thousands)
|
40,614
|
45,306
|
57,069
|
70,766
|
71,013
|
-
|
-
|
Reference price
2 |
51.94
|
84.06
|
20.14
|
15.15
|
11.28
|
11.28
|
11.28
|
Announcement Date
|
3/25/21
|
2/24/22
|
3/1/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
31.99
|
3.012
|
72.54
|
EBITDA
1 |
-
|
-118.6
|
-216
|
-225.9
|
-298.1
|
-232.7
|
-292.1
|
-298.7
|
EBIT
1 |
-
|
-118.8
|
-216.5
|
-227.3
|
-299.5
|
-240.3
|
-303
|
-281
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-751.27%
|
-10,059.08%
|
-387.39%
|
Earnings before Tax (EBT)
1 |
-
|
-118.1
|
-164.6
|
-221.3
|
-276.9
|
-187.2
|
-297
|
-250.4
|
Net income
1 |
-46.38
|
-118.5
|
-158.7
|
-236.8
|
-292.2
|
-196.5
|
-305.5
|
-286.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-614.32%
|
-10,143.51%
|
-394.75%
|
EPS
2 |
-8.160
|
-4.190
|
-3.720
|
-4.480
|
-4.470
|
-2.740
|
-3.724
|
-2.802
|
Free Cash Flow
1 |
-
|
-127.7
|
-205.3
|
-215.5
|
-208.4
|
-232.5
|
-286.6
|
-270.8
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-726.81%
|
-9,513.3%
|
-373.23%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/6/20
|
3/25/21
|
2/24/22
|
3/1/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
40.56
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-47.98
|
-
|
-
|
-
|
-51.4
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-48.19
|
-57.88
|
-63.46
|
-54.19
|
-51.75
|
-64.95
|
-103.9
|
-62.72
|
-67.92
|
-24.76
|
-67.75
|
-69.58
|
-78.2
|
-71.61
|
-73.55
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-61.06%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-48.1
|
-57.45
|
-63.04
|
-52.29
|
-48.52
|
-60.84
|
-99.46
|
-55.51
|
-61.07
|
10.18
|
-58.06
|
-60.79
|
-78.49
|
-69.75
|
-71.5
|
Net income
1 |
-50.06
|
-59.08
|
-68.36
|
-54.4
|
-54.97
|
-63.22
|
-112.5
|
-55.53
|
-60.92
|
10.07
|
-60.71
|
-63.8
|
-82.03
|
-71.17
|
-73.67
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
24.82%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.110
|
-1.310
|
-1.340
|
-0.9600
|
-0.9200
|
-1.070
|
-1.850
|
-0.7900
|
-0.8300
|
0.1400
|
-0.8503
|
-0.8858
|
-1.060
|
-0.9175
|
-0.9475
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/9/22
|
11/9/22
|
3/1/23
|
5/10/23
|
8/9/23
|
11/6/23
|
2/27/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
339
|
340
|
437
|
483
|
528
|
356
|
355
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-128
|
-205
|
-215
|
-208
|
-232
|
-287
|
-271
|
ROE (net income / shareholders' equity)
|
-
|
-104%
|
-47.2%
|
-59.4%
|
-67.1%
|
-49.4%
|
-102%
|
-123%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
7.520
|
8.000
|
7.320
|
6.180
|
6.340
|
3.870
|
3.500
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.76
|
6.11
|
2.55
|
0.58
|
6.44
|
2.8
|
3.95
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
20.13%
|
93.01%
|
5.45%
|
Announcement Date
|
3/6/20
|
3/25/21
|
2/24/22
|
3/1/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
11.28
USD Average target price
32.44
USD Spread / Average Target +187.63% Consensus |
1st Jan change
|
Capi.
|
---|
| -24.55% | 801M | | +12.08% | 116B | | +12.80% | 106B | | -9.80% | 23.89B | | -1.69% | 21.58B | | -10.60% | 18.96B | | -41.25% | 16.96B | | -14.49% | 16.33B | | +7.12% | 14.14B | | +31.75% | 12.02B |
Bio Therapeutic Drugs
|